Watch the replay of How I Think, How I Treat: Individualizing RCC Therapy in the Era of Immuno-Oncology, that was held on Thursday, November 5, 2020, is now available here.

Multimodality Therapy for Locally Advanced RCC Session

Palliation of the Unresectable Kidney Mass with Systemic Therapy

Presented by:  Elizabeth Wulff-Burchfield, MD

Imaging for Locally Advanced RCC (Node and Thrombus)

Presented by: Ivan Pedrosa, MD, PhD

Image Based Local Therapy for Oligometastatic Disease

Presented by: Rahul Sheth, MD

Non-Clear Cell RCC Session

Management of Multifocal Non-Clear Cell RCC

Presented by Mark Ball, MD

NRF2 and biallelic FH inactivation

Presented by: Aikseng Ooi, PhD

Response to Systemic Therapy in Patients with Metastatic Fumarate Hydratase (FH) Deficient RCC

Presented by: Jack Gleeson, MD

Pilot Study of Tremelimumab With or Without Cryoablation in Patients with mRCC

Presented by: Matthew Campbell, MD, MS

Immunotherapy and Emerging Therapies for RCC

Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC)

Presented by: Alex Chehrazi-Raffle, MD

Nivolumab 6 mg/kg plus ipilimumab 1 mg/kg (N6I1) every 8 weeks (Q8W) alternating with nivolumab 480 mg Q8W for first-line (1L) advanced renal cell carcinoma (aRCC): safety and efficacy from CheckMate 920

Presented by: Johanna Bendell, MD

Nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients without nephrectomy

Presented by: Nizar Tannir, MD

Association of the Neutrophil to Eosinophil Ratio with Response to Ipilimumab/Nivolumab in Metastatic Renal Cell Carcinoma

Presented by: Matthew Tucker, MD

Metabolism as a Target for RCC Session

Metabolic Adaptations in RCC and the Tumor Microenvironment

Presented by: Ed Reznik, PhD

Chromatin Dysregulation and ccRCC

Presented by: Lauren Banaszynski, PhD

Anti-Tumor Activity of Small Molecule Glutaminase Inhibitors: Role of Telaglenastat (CB-839) in RCC

Presented by: Nizar Tannir, MD

Metabolic gene signature as biomarker for recurrence in localized clear cell RCC

Presented by: Shuchi Gulati, MD

Multimodality Therapy for Metastatic RCC

IKCS: North America 2020 Keynote Address

New Therapies for Kidney Cancer Based on Studies of the Von Hippel-Lindau Tumor Suppressor Gene

Presented by: William G. Kaelin Jr., MD

Top Abstract Session

Associations between serum cytokine levels and gut microbiota composition in metastatic renal cell carcinoma

Presented by: Alex Chehrazi-Raffle, MD

Radiomic features of renal cell carcinoma metastatic sites can predict BAP1 mutation

Presented by: Luis Meza, MD

Phase 2 trial of lenvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC)

Presented by: Sumanta Pal, MD

An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution

Presented by: Yue Zhao, PhD

Lunch by the WoodFire

Treating Kidney Cancer in a Pandemic

Treating Kidney Cancer in a Pandemic Supplementary Videos

Surgical Triage During COVID-19

Presented by: Brian Shinder, MD

A Patient’s Perspective

Interview with Megan Conley

Lessons from COVID-19: Evolution of Clinical Practice for Systemic Therapy and Clinical Research

Presented by: Martin Voss, MD

Delaying Surgery for Clinical T1b-T2bN0M0 Renal Cell Carcinoma: Oncologic Implications in the COVID-19 Era and Beyond

Presented by: Arnav Srivastava, MD